Our findings support further evaluation of glutaminase inhibition, particularly CB-839, as a means to restore antitumor immunity in MTAP-deficient cancers and to enhance the efficacy of immune checkpoint blockade in tumors that are otherwise resistant. The gene discussed is GLS; the disease is cancer.